Search for:

Isabella F. C. Liu

Dr. Isabella Liu is the head of the Firm's Asia Pacific Intellectual Property and Technology Group. She advises clients on matters relating to the creation, exploitation and protection of IP rights. She is also responsible for the local IP Group's China and Hong Kong patent prosecution matters. Previously, Dr. Isabella Liu was the head of the Firm's Asia Pacific Healthcare and Life Sciences Industry Group for three years, leading a team of legal experts in this field cross multiple practices in the region. Dr. Liu is ranked as a leading lawyer in her field by top legal directories such as Chambers Asia Pacific for the Life Sciences category and IAM Patent. She has been complimented by clients that she possesses "a superb ability to understand the most complex technologies" and was noted for "advis[ing] in a way that is very commercial and strategic." Dr. Liu is also engaged as a regular guest lecturer by the University of Hong Kong's Department of Pharmacology and Pharmacy to share her expertise on intellectual property in the pharmaceutical industry with HKU students.

Regulatory measures came into force at the end of 2023 to facilitate cross-border transfers of personal data between Guangdong Province (“Guangdong”) and Hong Kong (“GBA Measures”). The recent relaxation of the cross-border data transfer (CBDT) regime at a national level may make the GBA Measures less appealing to some companies in the Chinese Mainland (“China” in this article, for the sake of brevity), but the GBA Measures will still be useful to companies which operate in Hong Kong and Guangdong that need to transfer sensitive personal data or large volumes of personal data across the Greater Bay Area, such as those in the healthcare and financial sectors, or those with a large base of data subjects in Guangdong and a regional office in Hong Kong that conduct cross-border transfers of personal data (e.g., customer data) on a regular basis.

From governments to private investors, big pharma to biotechs, organizations inside and outside the region are reimagining healthcare and life sciences to improve access, outcomes and affordability. This requires capital investment, collaboration and change at levels rarely seen before. In our digital campaign, we explore this dynamic through two main themes and identify six key market opportunities.

In June 2023, the Office of the Privacy Commissioner for Personal Data issued an updated Guidance on Data Breach Handling and Data Breach Notifications (“Guidance”). The Guidance updates a non-binding, end-to-end framework for data users to tackle data breaches, including recommended elements that go into a data breach response plan, questions that need to be addressed in the course of investigating a data breach incident, how to make a data breach notification and tips for preventing recurrence of data breaches.

In recent months, generative artificial intelligence has taken the world by storm.  Following plans to offer generative AI products announced by Chinese companies, the Cyberspace Administration of China released on 11 April 2023 the Measures for the Management of Generative Artificial Intelligence Services for public consultation. Following the consultation period, the interim measures were published on 13 July and take effect on 15 August.